Proactiveinvestors United Kingdom Redx Pharma Plc Proactiveinvestors United Kingdom Redx Pharma Plc RSS feed en Thu, 23 May 2019 23:00:27 +0100 Genera CMS (Proactiveinvestors) (Proactiveinvestors) <![CDATA[RNS press release - Update on Plans to Strengthen Balance Sheet ]]> Fri, 03 May 2019 11:34:52 +0100 <![CDATA[RNS press release - Redx to present two posters at AACR 2019 ]]> Fri, 29 Mar 2019 07:00:09 +0000 <![CDATA[RNS press release - Issue of Warrants and Change to Lease Agreement ]]> Thu, 28 Feb 2019 07:00:08 +0000 <![CDATA[RNS press release - Directorate Update ]]> Thu, 14 Feb 2019 07:00:11 +0000 <![CDATA[Media files - Redx Pharma chief "encouraged" by latest data on fibrosis drug candidate ]]> Wed, 13 Feb 2019 12:00:00 +0000 <![CDATA[News - Redx Pharma chief "encouraged" by latest data on fibrosis drug candidate ]]> Redx Pharma Plc’s (LON:REDX) chief executive Lisa Anson said she was “encouraged” by pre-clinical data from a fibrosis drug set to enter human trials next year.

Three independent studies assessed the potential efficacy of the company’s lead ROCK2 compound in animal models of lung, kidney and liver fibrosis.

WATCH: Redx Pharma chief "encouraged" by latest data on fibrosis drug candidate

The lab tests showed the Redx drug candidate was able to suppress collagen deposition and pathways associated with fibrosis, meaning it could have an impact on established forms of the disease.

Its profile suggests the putative treatment is suitable to be taken by mouth, rather than injected directly into the blood system.

Central role in fibrotic disease

ROCK2, or rho-associated coiled-coil containing protein kinase 2, is a protein that in humans regulates functions such as cell division and smooth muscle contraction.

It also plays a central role in metabolic and fibrotic disease, explained Dr Richard Armer, chief scientific officer of Redx.

“Generating highly selective ROCK2 inhibitors, without the significantly limiting hypotension observed with systemic use of existing non-selective ROCK1/2 inhibitors, has been a key research challenge,” he added.

“We are very encouraged to generate a highly selective ROCK2 inhibitor series where the lead compound has demonstrated anti-fibrotic effects pre-clinically in a broad range of organ models without any observed toxicity."

First-in-man studies

First-in-man studies of the ROCK2 technology will take place next year, focusing on people with NASH, or non-alcoholic liver disease.

“Liver fibrosis associated with NASH remains a condition with a clear unmet medical need and we hope that Redx's research into ROCK2 inhibition progresses into the clinic, potentially producing further data which could lead to a new treatment option for liver fibrosis patients," said CEO Anson.

The company’s most advanced and clinical-stage drug is a porcupine inhibitor. A phase I/II trial in people with solid tumours will re-start sometime in the first half.  

Tue, 12 Feb 2019 07:27:00 +0000
<![CDATA[RNS press release - New in vivo data on ROCK2 ]]> Tue, 12 Feb 2019 07:00:04 +0000 <![CDATA[News - Redx Pharma gets near £870,000 boost to working capital after repayment of loan previously written-off ]]> Redx Pharma PLC (LON:REDX) has received an unexpected cash injection following the repayment of a loan it made which had previously been written off in its accounts, giving it a near £870,000 boost to working capital.

The AIM-listed drug discovery and development company, focused on cancer and fibrosis, said that following the sale of significant assets by Redag Crop Protection Ltd (Redag), the repayment criteria for a loan previously granted to Redag by the company in October 2014 has been met.

READ: Redx Pharma exploring options with interested parties for its NBTI programme after Deinove declines to exercise option

As a result, the group confirmed, it has now received a full cash repayment of £869,126, representing the original capital amount of £713,948 plus outstanding interest to date.

The group said, as disclosed in its accounts for the year ended 30 September 2018, the loan was originally treated as a non-current receivable, subsequently impaired, and ultimately derecognised as an asset in the accounts for the year ended 30 September 2017, as a result of the conditionality attached to the repayment.

Notwithstanding this,  it added, the directors continued to seek repayment and are pleased that this has now been achieved.

The funds will be used to augment working capital and, accordingly, the cash receipt will be disclosed in the group’s statement of comprehensive income for the year ending 30 September 2019.

Wed, 06 Feb 2019 11:55:00 +0000
<![CDATA[RNS press release - Receipt of Outstanding Loan ]]> Wed, 06 Feb 2019 11:25:31 +0000 <![CDATA[News - Redx Pharma exploring options with interested parties for its NBTI programme after Deinove declines to exercise option ]]> Redx Pharma Plc (LON:REDX) is exploring options for Novel Bacterial Topoisomerase Inhibitor (NBTI) programme with other parties potentially interested in licensing the project after Deinove said it has decided not to exercise their option.

The AIM-listed drug discovery and development company focused on cancer and fibrosis said the decision by Deinove follows a period of nine months of evaluation during which the group had sole rights to develop the programme.

WATCH: Redx Pharma receives approval to re-commence clinical trial of RXC004

The group added that all rights to the NBTI programme, including all new data generated by Deinove, now revert to Redx.

The firm entered into an option and license agreement with Deinove for the NBTI programme in March 2018 following a strategic decision to close the Redx anti-infectives unit in 2017, and focus on developing new medicines in Oncology and Fibrosis. 

Last week, Redx announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has given formal approval to the company to re-commence the phase 1/2a trial for RXC004, an oral porcupine inhibitor targeting the Wnt signalling pathway.

It said clinical evaluation of RXC004 in patients with advanced solid tumours remains on track to resume in H1 2019 following the approval of a revised phase 1/2a clinical trial protocol and drug formulation.

Thu, 31 Jan 2019 08:42:00 +0000
<![CDATA[RNS press release - Deinove return rights to Redx Programme ]]> Thu, 31 Jan 2019 07:00:02 +0000 <![CDATA[RNS press release - Results of Annual General Meeting ]]> Wed, 23 Jan 2019 11:25:18 +0000 <![CDATA[Media files - Redx Pharma receives approval to re-commence clinical trial of RXC004 ]]> Tue, 22 Jan 2019 11:32:00 +0000 <![CDATA[News - Redx receives regulatory green light to restart research ]]> Redx Pharma Plc (LON:REDX) saw its shares jump on Monday after the firm said it had received the regulatory green light to re-commence its phase I/II clinical trial of RXC004 on people with solid tumours.

It means the company is on track to restart the study as planned in the first-half.

RXC004 is a new breed of cancer drug called a porcupine inhibitor, with this particular formulation targeting the Wnt signalling pathway, which known to be heavily involved in cell growth and division.

READ: First data for Redx Pharma’s RXC006 fibrosis candidate shows compound has “great potential”

Patients receiving the oral medication will do so at much lower starting doses than originally planned.

“We have learnt a significant amount from the first patient treated with RXC004, and this provides the basis for an optimised RXC004 development plan as well as the confidence to evaluate the clinical potential of RXC004 in cancer patients,” said Natalie Cook, consultant oncologist and principal investigator from the Christie Hospital in Manchester.

Redx chief executive Lisa Anson said she believes the putative treatment has potential used on its own and in combination with standard of care treatments.

“We look forward to working closely with our expert clinical oncology colleagues across the U.K. on this exciting programme,” she added.

In early morning trading, Redx shares were 10.7% higher at 7.75p.

 -- Adds share price --

Mon, 21 Jan 2019 07:48:00 +0000
<![CDATA[RNS press release - RXC004 Trial Approval ]]> Mon, 21 Jan 2019 07:00:06 +0000 <![CDATA[RNS press release - Second Price Monitoring Extn ]]> Thu, 10 Jan 2019 14:05:56 +0000 <![CDATA[RNS press release - Price Monitoring Extension ]]> Thu, 10 Jan 2019 14:00:49 +0000 <![CDATA[RNS press release - Redx to present at 2019 Biotech Showcase event ]]> Thu, 03 Jan 2019 07:00:11 +0000 <![CDATA[RNS press release - Publication of Annual Report and Accounts ]]> Fri, 28 Dec 2018 11:47:55 +0000 <![CDATA[News - First data for Redx Pharma’s RXC006 fibrosis candidate shows compound has “great potential” ]]> The first pre-clinical data for Redx Pharma Plc’s (LON:REDX) RXC006 drug candidate has suggested that the compound has “great potential” as a fibrosis treatment.

RXC006 is what’s known as a Porcupine inhibitor. They work by dialling down the Porcupine protein, which is the control switch for the Wnt pathway – widely believed to be heavily involved in the scarring process in the lung typical of idiopathic pulmonary fibrosis.

READ: Redx hails new fibrosis candidate

This first batch of in-vivo data showed that the compound was “highly effective” in suppressing the Wnt pathway and lung fibrosis.

Suppression of both liver and kidney fibrosis has also been shown in animal models.

“The data suggests that RXC006 has great potential to treat fibrosis in human patients,” said chief scientific officer Richard Amer.

“Redx are progressing RXC006 towards the clinic for the treatment of Idiopathic Pulmonary Fibrosis and plan to initiate first in man clinical trials during 2020.”

Fri, 30 Nov 2018 07:24:00 +0000
<![CDATA[RNS press release - First RXC006 data for treatment of fibrosis ]]> Fri, 30 Nov 2018 07:00:04 +0000 <![CDATA[Media files - Redx Pharma's CSO Richard Armer outlines development ambitions and clinical targets ]]> Tue, 20 Nov 2018 09:30:00 +0000 <![CDATA[Media files - Redx Pharma CEO focused on driving fibrosis and oncology assets into the clinic ]]> Mon, 19 Nov 2018 15:13:00 +0000 <![CDATA[News - Redx Pharma appoints CFO as it publishes annual results ]]> Redx Pharma Plc (LON:REDX) pharma announced the appointment of a new chief financial officer at the same as presenting its figures for the last financial year.

Dr James Mead, who has held senior roles at AstraZeneca, will take over from interim incumbent Dominic Jackson on February 1.

READ: Redx Pharma hails new fibrosis drug candidate

"I am delighted to have James join our team at Redx. He will bring a dynamic and professional approach and will play an integral role as we focus on progressing delivery of our strategy,” said chief executive Lisa Anson.

The 41-year-old joins the business at an exciting. Having defined a new strategy under the guidance chairman Iain Ross after a period in administration, Redx is ready to begin first-in-man trials of lead oncology drug, RXC004, in the first half of next year.

Treatments for cancer and fibrosis 

Putative fibrosis treatment RXC006 is expected to enter the clinic the year after.

Financially, the benchmark for small drug discovery groups such as Redx is cash in the bank. As at the period-end it had £6.5mln, the equivalent of three-quarters of the company’s current market capitalisation.

As is common for businesses at this early stage of development, Redx was loss-making. The deficit for the year ended September 30 was £8.8mln, with operating expenditure reduced £5.2mln to £10.6mln.

Chairman Ross said: "This set of results confirms that Redx is operationally a stronger and leaner company led by an ambitious new management team, with a clear strategic direction. 

“Lisa Anson has made a major impact and under her leadership, the group is starting to make real progress in our programmes aimed at creating high-value drugs that treat significant unmet need in cancer and fibrosis.”

Mon, 19 Nov 2018 07:29:00 +0000
<![CDATA[RNS press release - Preliminary Results for year ended 30 Sept 2018 ]]> Mon, 19 Nov 2018 07:00:06 +0000 <![CDATA[News - Redx Pharma hails new fibrosis drug candidate ]]> Redx Pharma Plc (LON:REDX) has unveiled a new drug candidate, which will enter clinical trials in 2020.

RXC006 is a new breed of pill called a porcupine inhibitor and it will be used as a first-in-class treatment for a rare but life-threatening disease called idiopathic pulmonary fibrosis.

READ: Redx Pharma poster assesses the direct tumour targeting of cancer candidate

Known as IPF for short, it is a chronic lung condition with a very poor prognosis and limited medication options.

Developing a drug for a small patient group where there is no drug specifically designed to treat the ailment can often speed up the long process of gaining regulatory approval. It should be stressed, Redx hasn’t discussed this aspect in the latest update.

It did, however, say, RXC006 has performed well in pre-clinical studies. Redx said it had been “potent and highly effective at suppressing the Wnt pathway”.

The Wnt pathway essentially helps regulate gene transcription, cell shape and the amount of calcium in the cell.

Redx has shown the involvement of the Wnt pathway increases with disease severity in IPF.

It is hoped RXC006 can offer patients with a severe form of the disease a drug option where there is currently no effective therapy beyond palliative care.

“IPF is a devastating disease with little effective treatment and there is, therefore, a clear unmet need for new therapies,” said chief executive Lisa Anson.

“Redx is excited to bring its precision medicinal chemistry expertise to bear with the discovery of this novel drug candidate. We look forward to taking RXC006 into clinical development; we plan to enter first in man clinical trials during 2020, in line with our strategy."

Wed, 14 Nov 2018 07:58:00 +0000
<![CDATA[RNS press release - Redx announces new drug development candidate ]]> Wed, 14 Nov 2018 07:00:02 +0000 <![CDATA[News - Redx Pharma poster assesses the direct tumour targeting of cancer candidate ]]> Redx Pharma Plc (LON:REDX) will unveil a poster presentation outlining some encouraging data pointing to the direct tumour targeting effects of RXC004, its porcupine inhibitor.

The new information was garnered using colorectal and pancreatic cancer cell lines.

Redx concluded that cancer cells carrying RNF43 mutations or RSPO fusions were sensitive to RXC004 in its tests.

As such, the company believes it would be most effective as a single therapy in patients with cancers carrying those markers.

Patient screening 

This, it added, would support by a genetically-defined patient selection strategy for ongoing RXC004 clinical studies.

A phase I/IIa trial of the porcupine inhibitor is set to resume in the first half of next year in patients with what are described as “advanced malignancies”.

A poster summarising the latest data will be presented to the National Cancer Research Institute in Glasgow from noon Monday.

"We are delighted to showcase some of the fantastic science happening at Redx,” said the company’s chief medical officer, Richard Armer.

“We are encouraged by the preclinical data presented at the NCRI, which demonstrates the exquisite sensitivity of specific genetically defined cancer models to our Porcupine inhibitor, RXC004.

“The strength of these data highlight some of the broad and multiple options available for the future development of this programme as we look to re-enter the clinic in the first half of 2019."

Mon, 05 Nov 2018 07:38:00 +0000
<![CDATA[RNS press release - Preclinical data presented at cancer conference ]]> Mon, 05 Nov 2018 07:00:06 +0000 <![CDATA[RNS press release - Notice of Results ]]> Wed, 31 Oct 2018 07:00:07 +0000 <![CDATA[News - Redx Pharma chief elected to industry body role ]]> Redx Pharma Plc (LON:REDX) has confirmed its chief executive, Lisa Anson, has been elected to senior industry role.

From the start of 2019, she will serve as a director of the UK BioIndustry Association for a three-year term.

READ: Redx Pharma to focus on progressing oncology and fibrotic drugs in 2019

"I am delighted to be elected to join the BIA Board,” said Anson.

“I am passionate about the UK Biotech sector, as it is not only the focus for much of the exciting science in the UK, but it is also an important sector supporting the UK economy.

“Having previously been president of the Association of the British Pharmaceutical Industry (ABPI), I am personally excited at the prospect of working with the BIA to further the industry."

Mon, 29 Oct 2018 07:52:00 +0000
<![CDATA[RNS press release - Redx notes election of Lisa Anson to UK BIA BOD ]]> Mon, 29 Oct 2018 07:00:08 +0000 <![CDATA[News - Redx Pharma poster hails the potential of new class of kidney and liver drug ]]> Richard Armer, chief scientific officer of Redx Pharma Plc (LON:REDX), believes the company’s new ROCK2 inhibitor drug has the potential to be a “best-in-class agent” for the treatment of fibrotic diseases of the kidney and liver.

His comments came at the conclusion of the American Society of Nephrology’s Kidney Week, in San Diego, California, at which Redx made a poster presentation hailing the potential of using the therapy to tackle chronic kidney disease.

Highly selective ROCK2 inhibitors are thought to suppress the release of pro-fibrotic factors from kidney mesangial cells.

Reduced damage

In an animal model of acute kidney injury, the Redx selective ROCK2 compound reduced damage and the expression of inflammatory and profibrotic genes in the kidney.

In addition, a rat study indicated that the Redx inhibitor avoided cardiovascular side-effects.

"We are pleased that our poster was presented at the high profile American Society of Nephrology Kidney Week,” said Armer.

“We believe our highly selective ROCK2 inhibitors have the potential to be best-in-class agents for the treatment of fibrotic diseases of the kidney such as diabetic nephropathy and of the liver such as non-alcoholic steatohepatitis.

“This is the first publication of our ROCK2 project data and we are delighted that the high quality of our research has been recognised by the ASN."

Fri, 26 Oct 2018 07:29:00 +0100
<![CDATA[RNS press release - Details from Redx ROCK2 inhibitor poster ]]> Fri, 26 Oct 2018 07:00:02 +0100 <![CDATA[RNS press release - Redx ROCK2 inhibitors poster to be presented ]]> Mon, 22 Oct 2018 07:00:08 +0100 <![CDATA[News - Redx Pharma to focus on progressing oncology and fibrotic drugs in 2019 ]]> Redx Pharma Plc’s (LON:REDX) new management team plans to focus its cash resources on progressing its drug leads in oncology and fibrotic disease to clinical proof-of-concept in 2019.

Following an extensive internal review, Redx’s new CEO – former AstraZeneca (LON:AZN) UK president Lisa Anson – has set out plans for a slimmed-down pipeline in the two disease areas, with the aim of progressing the drugs to the clinical proof-of-concept stage, broker Hardman & Co said in a note to clients on Tuesday.

READ: Redx Pharma ready to relaunch with AstraZeneca’s former UK boss now at the helm

Next year will be an important year for the firm with the re-start of Phase I/IIa trial for RXC004, part of a niche, and potentially breakthrough group of cancer drugs called Porcupine inhibitors. They work by dialling down the Porcupine protein, which is the control switch for the Wnt pathway – known to be heavily involved in cell growth and division.

Hardman & Co said under Anson, Redx now has a clear vision and a streamlined pipeline focused on "high unmet needs in oncology and fibrotic diseases", and the ability to leverage its medicinal chemistry expertise.

The AIM-quoted biotech also aims to nominate one to two development candidates from a portfolio of three fibrosis programmes, with first clinical trials in 2020.

“After a difficult period, Redx has emerged in much better shape. While all early-stage pharma and biotech companies carry substantial risks and are capital intensive, the rewards can be substantial, as evidenced by the successful disposal of its BTK programme for £30.5mln in cash in 2017,” Hardman analysts added.

Shares in Redx were 1.1% down at 8.60p in mid-afternoon trade.

Tue, 02 Oct 2018 14:47:00 +0100
<![CDATA[Media files - Redx Pharma's chief medical officer discusses lead oncology drug RXC004 ]]> Mon, 10 Sep 2018 08:26:00 +0100 <![CDATA[Media files - Redx Pharma confirms restart of clinical trial for lead cancer drug in H1 2019 ]]> Tue, 04 Sep 2018 13:57:00 +0100 <![CDATA[News - Redx Pharma receives regulatory green light to restart cancer trial ]]> Redx Pharma PLC (LON:REDX) has confirmed it will restart a Phase I/IIa clinical trial of its lead cancer drug in the first half of next year – but at a much reduced dose.

It follows what it described as a “positive” meeting with the Medicines and Healthcare products Regulatory Agency, the drugs watchdog.

WATCH: Redx Pharma's chief medical officer discusses lead oncology drug RXC004

As well as the newly-proposed lower starting dose of RXC004, there will be a revised study protocol, including enhanced safety monitoring.

If it successfully negotiates this early phase clinical assessment, the drug will then be tested in harness with immune checkpoint inhibitors to target solid tumours such as colorectal cancer.

RXC004 is one of a new breed of immune-oncology treatments currently in clinical development.

The so-called Porcupine inhibitor helps enhance the body’s own immune system to tackle what is known as cold tumours that avoid detection by turning them ‘hot’.

Redx chief executive Lisa Anson said she was “pleased” the previously-suspended trial had received the green light to restart.

“We look forward to submitting our final protocol amendments, with the aim of initiating the next patient in the first half of 2019,” she added.

“I would like to thank my colleagues at Redx and our clinical investigators for all their hard work that has resulted in our phase I/IIa proposal being positively received by the MHRA.”

Tue, 04 Sep 2018 07:52:00 +0100
<![CDATA[RNS press release - Redx Pharma Announces Way Forward For RXC004 ]]> Tue, 04 Sep 2018 07:00:05 +0100 <![CDATA[Media files - New Redx CEO bringing leadership and skills to 'capitalise on its great science' ]]> Wed, 18 Jul 2018 16:13:00 +0100 <![CDATA[News - Redx Pharma looks for some Porcupine help in its fight against cancer and fibrosis ]]> It has been a rough 18 months or so for Redx Pharma PLC (LON:REDX), the AIM-quoted biotech which specialises in developing cancer and fibrosis-fighting drugs.

The company fell into administration last May when Liverpool City Council called in a £2mln loan. Unlike most though, Redx was out again within a few months, having sold off its BTK inhibitor technology and drug development programme to a Nasdaq-listed Loxo Oncology for the princely sum of £30mln (US$40mln).

With the dust settling and shares back to trading on AIM, the drug developer brought in an industry heavyweight in the form of Lisa Anson, who took the reins in June.

READ: Redx shares surge as AstraZeneca's UK boss appointed new CEO

Anson was the president of AstraZeneca PLC’s (LON:AZN) UK division immediately prior to joining Redx, while she also held various other senior leadership roles during her 20-year career at the FTSE 100-drugs giant.

To some, it may seem like a drop down the divisions, but the Cambridge-educated scientist-turned-businesswoman insists this is an “exciting opportunity” to make her mark on the UK life sciences sector.

That’s something she is clearly passionate about, as evidenced by her role as the president of the Association of the British Pharmaceutical Industry.

“I feel I can bring some leadership which will make a difference at Redx, where I think there’s some really strong science,” says Anson.

“We need to now relaunch the company and build it ready for growth so for me that’s an exciting opportunity.”

One of the first things on her to-do list is to get RXC004, the company’s lead drug, back into trials.

Porcupine inhibitors: Animal rescue?

The first patient in a Phase I/II trial was dosed back in February but Redx paused the study just over a month later, admitting that the dosing levels it had thought were right based on its pre-clinical research were actually too high.

Since then, it has been talking with regulators about lowering the dose and getting the trial back up and running again which it expects will happen in the first half of 2019.

“If we didn’t believe this drug had a window that could hit the target at a safe dose, we wouldn’t be going back into the clinic with it,” says Anson.

READ: Redx confirms RXC004 trial will resume early next year

Despite the temporary setback, Redx still has a lot of belief in RXC004, which is part of a niche, and potentially breakthrough group of cancer drugs called Porcupine inhibitors.

They work by dialling down the Porcupine protein, which is the control switch for the Wnt pathway – known to be heavily involved in cell growth and division.

“What you’re doing is readjusting the control switch (Porcupine) of one of the main pathways (Wnt) which controls the division of cells and thereby stopping the proliferation of cells (A.K.A cancer),” explains the new CEO.

Potential as a combination therapy

Now not all cancers are driven by the Wnt pathway, but the hope is that RXC004 will inhibit the growth of those which are.

Interestingly, there’s a growing bank of research that suggests Porcupine inhibitors may also be very effective in tandem with checkpoint inhibitors such as anti-PD-1, which lower or break cancer’s defence against the body’s immune system.

That’s why Anson and her team still plan to assess the drug in combination with a checkpoint inhibitor further down the line, something Swiss giant Novartis is doing with its Porcupine inhibitors.

Away from RXC004, Redx has a few other anti-cancer candidates, although they are still in pre-clinical development.

Fibrosis the other focus

Porcupine inhibitors aren’t just proving useful in the fight against cancer; more and more researchers are forming the opinion that they can be used to combat fibrosis.

The Wnt pathway is widely believed to be heavily involved in the tissue scarring process which is typical of idiopathic pulmonary fibrosis.

“The second leg of the company is the whole area of fibrosis, [which] is something we can really focus on. There are very few drugs in the market that actually tackle fibrosis, most of them are anti-inflammatory and don’t treat the fibrosis itself,” says Anson.

“Redx has some great agents against fibrosis so that’s another area of the business that I think we need to focus on developing alongside the 004 programme.”

READ: Redx Pharma's RXC006 compound shows fibrosis promise

One of those agents is RXC006, which has impressed in early pre-clinical trials.

Redx said the first batch of in-vivo data suggested the compound has “great potential” as a fibrosis treatment and it plans to kick off in-human clinical trials in 2020.

Fibrosis could prove to be a lucrative area as well, given that fibrosis can occur in many tissues within the body, affecting millions of people around the world. Some of the better-known examples are pulmonary fibrosis (lungs), cirrhosis (liver) and Crohn’s disease (intestine).

Sticking to what it knows

Those two areas will remain the focus for the foreseeable future as well, says Anson.

“We’re a small company and we really to make sure we deliver on the exciting assets that we’ve [already] got. Our priorities are to make sure we get RXC004 back into the clinic and to make sure that we accelerate the development of the fibrosis compounds.

“Behind that we have a series of programmes that we’re looking at that will build the next generation of assets but we’re not going to be looking outside of oncology and fibrosis.”

Tue, 17 Jul 2018 14:35:00 +0100
<![CDATA[RNS press release - Directorate Update and Grant of Options ]]> Mon, 04 Jun 2018 07:00:12 +0100 <![CDATA[News - Redx Pharma up as it confirms cancer drug clinical trial will re-start early next year ]]> Redx Pharma plc(LON:REDX) shares gained on Wednesday as the group confirmed it will restart early-stage clinical trials on its cancer drug after discussion with the regulator.

The phase I/IIa assessment of RXC004 was halted in March amid concerns the initial dosing was too high.

Crucially, there were no other 'off-target' side-effects, while the compound appeared to act in the way expected.

Following talks with the Medicines and Healthcare Regulatory Agency, work will restart early next year at a lower initial dose.

First-half results

The update was provided alongside first-half results, which showed Redx to be in a financially strong position with just over £10mln in the bank as at March 31.

The company, which recently unveiled senior AstraZeneca executive Lisa Anson  its new chief executive, has also managed to cut £7mln from costs on an annualised basis.

It meant that Redx's loss fell to £4.6mln in the six months from £10.7mln.

"I am pleased with the progress that Redx has made in the past six months," said chairman Iain Ross.  

"We have continued to advance our R&D programmes and achieved substantial cost savings across the business."

In mid-morning trading, Redx shares were 1.9% higher at 13.75p.

-- Adds share price --


Wed, 30 May 2018 07:55:00 +0100
<![CDATA[RNS press release - Interim Results ]]> Wed, 30 May 2018 07:00:07 +0100 <![CDATA[News - Redx Pharma shares soar 69% as executive chairman increases stake ]]> Redx Pharma Plc (LON:REDX) shares soared as the company announced that Iain Ross, its executive chairman, has today acquired 150,000 Redx oridinary shares at a price of 11p per share.

The drug developer said following this acquisition, Iain Ross will hold 600,000 ordinary shares in the company, representing 0.47% of the issued share capital.

Yesterday Redx Pharma's shares jumped 48% as the company announced the appointment of AstraZeneca PLC (LON:AZN) Lisa Anson as its new chief executive.

READ: Redx Pharma shares soar 48% after it recruits heavy hitter from drugs major AstraZeneca

In lunchtime trading company’s shares soared 69.2% to 16.5p.


Wed, 25 Apr 2018 12:00:00 +0100
<![CDATA[RNS press release - Share Purchase by Chairman ]]> Wed, 25 Apr 2018 10:57:23 +0100 <![CDATA[RNS press release - Second Price Monitoring Extn ]]> Wed, 25 Apr 2018 09:05:56 +0100 <![CDATA[RNS press release - Price Monitoring Extension ]]> Wed, 25 Apr 2018 09:00:39 +0100 <![CDATA[News - Redx Pharma shares soar 48% after it recruits heavy hitter from drugs major AstraZeneca ]]> Shares in drug discovery group Redx Pharma PLC (LON:REDX) soared 48% after it pulled off a major coup with the appointment of a senior executive from drugs giant AstraZeneca PLC (LON:AZN) as its new chief executive.

She is 49-year-old Lisa Anson, who has been AZ’s UK president since 2012 and has worked for the company for more than two decades.

Anson, who has an MBA from the prestigious INSEAD business school and a first in natural sciences from Cambridge, joins Redx in June.

READ: Redx Pharma inks option and licence agreement for NBTI programme

Chairman Iain Ross, who took executive control following the departure of former CEO Neil Murray, will step back to a non-executive role, the company said in a statement.

Substantial biotech company 

He said: “Following the events of 2017 Lisa has been tasked by the Board to lead the re-launch of the company and to take the steps necessary to build a substantial biotech company built upon an innovative science base, selectively acquiring additional assets, if appropriate.

“Lisa is a consummate business professional, who brings a wealth of relevant experience from the international pharmaceutical and biotech sector. 

“I am confident that, as CEO, she is the right person to grow this company into a very exciting and meaningful entity that has the potential to create both important new medicines for patients and generate significant value for shareholders."

Those events referred to by Ross included suspension of trading in Redx shares and the sale of one of its leading assets.

Mentioned above, the shares reacted positively to the news, advancing 48% to 9.24p.

Best-in-class drugs 

Redx is focused on creating and developing first-, or potentially best-in-class drugs for cancer and fibrosis that address significant unmet medical needs.

Its flagship drug is RXC004, a porcupine inhibitor, a new and potentially breakthrough method of fighting cancer.

Porcupine inhibitors work by targeting cancer stems cells that can often lie dormant after traditional treatment and are associated with a recurrence of the illness.

The thinking goes that if you kill the stem cells, you have a chance of eradicating the disease completely.

Growing bank of research 

There is a growing bank of research that has found they may also be very effective in tandem with checkpoint inhibitors such as anti-PD-1, which lower or break cancer’s defence against the body’s immune system.

That’s why Redx has a twin track approach. RXC004 is currently undergoing a Phase I clinical trial as a single therapy targeted at gastric, biliary and pancreatic cancers.

At the same time, preparations are being made to for an early stage study of the drug in harness with an anti-PD-1 to combat melanoma.

The firm is also developing a porcupine drug for conditions such as non-alcoholic steatohepatitis hepatic fibrosis, or NASH for short.

It is the pick of a healthy early-stage programme that includes a tie-up with AstraZeneca, details of which are not currently in the public domain.

Tue, 24 Apr 2018 07:54:00 +0100